Virios Therapeutics

ACTIVE

44 Milton Ave, Alpharetta, 佐治亚州, United Stateswww.virios.comPublic4 employeesEstablished: 2012-01-01

Also known as:

virios therapeutics, inc.

viri.us

VIRI

Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”) and Long-COVID (“LC”). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2012

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

100.0%

Trial Status Distribution

Completed

100.0%

Clinical Trials

Trials sponsored by this organization (1)

Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1

Phase 2

Completed

interventional

Jun 2021422 participants

Approvals

No approval data available

News

Virios Therapeutics and Wex Pharmaceuticals Merge to Form Dogwood Therapeutics, Advancing Novel Pain and Viral Therapies

- Virios Therapeutics and Wex Pharmaceuticals have merged in an all-stock transaction, creating Dogwood Therapeutics (NASDAQ: DWTX), focused on clinical development of Halneuron®, IMC-1, and IMC-2. - The merger includes a $19.5 million financing to advance Halneuron®, a non-opioid NaV1.7 inhibitor for chemotherapy-induced neuropathic pain, with Phase 2b interim results expected in 2H25. - Dogwood Therapeutics will grant existing VIRI stockholders a contingent value right (CVR) tied to potential milestone payments from partnering transactions for IMC-1 (fibromyalgia) and IMC-2 (Long-COVID). - A 25-for-1 reverse stock split was executed to enable the business combination and Nasdaq listing compliance, with Dogwood Therapeutics trading under the ticker symbol "DWTX" starting October 9, 2024.

Oct 7, 2024

Back to Organizations